Table 1

Baseline characteristics of study participants

All patients (n=224)MACCEP values
No (n=168)Yes (n=56)
Age
 Mean - years61.7 (±7.9)61.7 (±7.8)61.7 (±8.2)0.981
 Distribution - no. (%)
 ≤60 years100 (44.6)75 (44.6)25 (44.6)1
 >60 years124 (55.4)93 (55.4)31 (55.4)1
Male sex - no. (%)180 (80.4)136 (81.0)44 (78.6)0.698
Body mass index (kg/m2)25.9 (±2.9)25.9 (±2.8)25.9 (±3.2)0.970
Current smoking - no. (%)133 (59.4)103 (61.3)30 (53.6)0.307
Medical history - no. (%)
 Hypertension159 (71.0)121 (72.0)38 (67.9)0.552
 Diabetes mellitus83 (37.1)59 (35.1)24 (42.9)0.299
 Chronic obstructive pulmonary disease2 (0.9)1 (0.6)1 (1.8)0.412
 Peripheral vascular disease7 (3.1)5 (3.0)2 (3.6)0.825
 Prior MI76 (33.9)55 (32.7)21 (37.5)0.515
 Chronic kidney disease3 (1.3)3 (1.8)0 (0.0)0.314
Ejection fraction (%)60.5 (±7.6)60.5 (±7.6)60.4 (±7.9)0.923
Rosuvastatin use in the STICS trial110 (49.1%)84 (50.0%)26 (46.4%)0.643
Medication use after discharge - no. (%)
 Aspirin217 (96.9)163 (97.0)54 (96.4)0.825
 β-blocker163 (72.8)124 (73.8)39 (69.6)0.544
 Statins158 (70.5)120 (71.4)38 (67.9)0.612
 ACEI52 (23.2)40 (23.8)12 (21.4)0.715
 Calcium channel blocker52 (23.2)36 (21.4)16 (28.6)0.273
Scheduled surgery - no. (%)
 On-pump procedure101 (45.1)72 (42.9)29 (51.8)0.245
 Off-pump procedure123 (54.9)96 (57.1)27 (48.2)0.245
  • Values are mean (±SD) or n (%).

  • ACEI, ACE inhibitors; MACCE, major adverse cardiac and cerebrovascular events; MI, myocardial infarction; STICS, Statin Therapy in Cardiac Surgery.